ACT Biotech Inc.
This article was originally published in Start Up
Oncology-focused ACT Biotech acquired its oral kinase programs from Bayer when it merged with Schering. The start-up's lead compound is telatinib, a potent and selective orally available inhibitor of three receptor tyrosine kinases. According to ACT, it is the most selective kinase inhibitor yet developed. That selectivity imparts an excellent safety profile, which makes it well tolerated at high, continuous doses. The candidate also has no overlapping side effects with other chemotherapy drugs.
You may also be interested in...
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Advancing the Technological Frontier in AAA Repair," features profiles of Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed. Plus these Start-Ups Across Health Care: ACT Biotech, Ausio Pharmaceuticals, CureFAKtor Pharmaceuticals, Harbor MedTech and Insituvue.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.